Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Leslie Gillin Sells 3,759 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) Director Leslie Gillin sold 3,759 shares of the stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $67.62, for a total value of $254,183.58. Following the completion of the transaction, the director now owns 3,599 shares in the company, valued at approximately $243,364.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Establishment Labs Trading Down 1.4 %

Shares of ESTA stock opened at $69.55 on Friday. Establishment Labs Holdings Inc. has a 12 month low of $44.03 and a 12 month high of $93.80. The company has a quick ratio of 2.91, a current ratio of 3.85 and a debt-to-equity ratio of 97.56. The business’s 50 day moving average is $68.90 and its two-hundred day moving average is $63.37. The company has a market cap of $1.70 billion, a PE ratio of -22.65 and a beta of 1.03.

Establishment Labs (NASDAQ:ESTA – Get Rating) last announced its quarterly earnings results on Monday, February 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.16. Establishment Labs had a negative return on equity of 422.08% and a negative net margin of 46.51%. The company had revenue of $43.81 million for the quarter, compared to the consensus estimate of $43.70 million. Equities analysts predict that Establishment Labs Holdings Inc. will post -2.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Mizuho increased their price objective on Establishment Labs from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, January 24th. Stephens increased their price objective on Establishment Labs from $87.00 to $89.00 and gave the stock an “overweight” rating in a report on Tuesday, February 28th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $100.86.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Voya Investment Management LLC grew its stake in shares of Establishment Labs by 3.6% in the fourth quarter. Voya Investment Management LLC now owns 272,033 shares of the company’s stock worth $17,859,000 after acquiring an additional 9,531 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Establishment Labs in the fourth quarter worth $1,249,000. Legal & General Group Plc grew its stake in shares of Establishment Labs by 2.3% in the fourth quarter. Legal & General Group Plc now owns 6,965 shares of the company’s stock worth $457,000 after acquiring an additional 157 shares during the last quarter. Morgan Stanley grew its stake in shares of Establishment Labs by 98.3% in the fourth quarter. Morgan Stanley now owns 302,422 shares of the company’s stock worth $19,854,000 after acquiring an additional 149,925 shares during the last quarter. Finally, Man Group plc acquired a new stake in shares of Establishment Labs in the fourth quarter worth $217,000. Institutional investors and hedge funds own 75.26% of the company’s stock.

Establishment Labs Company Profile

(Get Rating)

Establishment Labs Holdings, Inc is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm’s products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2.